Zika Virus
Issue 30  |  June 2016
Euroimmun's world-first commercial
serological diagnostic tests for Zika Virus

Zika Virus

Zika Virus ELISA and IIFT tests have been registered with the Australian Register of Therapeutic Goods (ARTG)

Euroimmun's ELISA and IIFT tests have been successfully registered with the ARTG. These tests allow for confident determination of IgG and IgM antibodies against the virus in blood samples.

The Euroimmun tests can detect both acute infections (in most cases from the fifth day after onset of symptoms) and past infections. Test systems for direct virus detection (e.g. PCR) are only able to detect infections up to five days after onset of symptoms - after this, the virus itself is no longer detectable.


Anti-Zika Virus ELISA (IgG/IgM) 

This is based on very specific recombinant NS1 antigens, which are produced in Euroimmun laboratories. Reduced cross-reactivity to other flaviviruses (including TBEV or YFV vaccinated patients) allows for very high specificity. Positive results are a clear indicator of infection.
98-100% specificity (Huzly et al)
100% sensitivity, 97% specificity (Dr Gosink
100% agreement with CDC MAC-ELISA, no cross-reactions with sera from early convalescent stage dengue infections (100% specificity), or with sera from suspected secondary Dengue infections (100% specificity) (Granger et al)
This ELISA is used by the WHO Collaboration Centre in Hamburg, Germany (Frank et al)
Available now.
Order code: EI 2668-9601 G/M

IIFT Arbovirus Fever Mosaic 2 (IgG/IgM) 

This mosaic allows for investigation of other viral fever diseases in parallel. This is helpful for differential diagnosis, given the similarity in symptoms and transmission with Dengue and Chikungunya.
96-99% sensitivity, 95-100% specificity (Dr Gosink).
Available now.

Order code: FI 2668-1 G/M

Contact Australia
Contact NZ
Copyright © 2016 ESL Biosciences Australia (2012) Pty Ltd. All rights reserved.
unsubscribe from this list  |  update subscription preferences